0000930413-11-005171.txt : 20110808 0000930413-11-005171.hdr.sgml : 20110808 20110808112452 ACCESSION NUMBER: 0000930413-11-005171 CONFORMED SUBMISSION TYPE: 8-K/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20110510 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20110808 DATE AS OF CHANGE: 20110808 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ENZON PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000727510 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 222372868 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 000-12957 FILM NUMBER: 111016115 BUSINESS ADDRESS: STREET 1: 20 KINGSBRIDGE ROAD STREET 2: ATT: GENERAL COUNSEL CITY: PISCATAWAY STATE: NJ ZIP: 08854 BUSINESS PHONE: 732-980-4500 MAIL ADDRESS: STREET 1: 20 KINGSBRIDGE ROAD STREET 2: ATT: GENERAL COUNSEL CITY: PISCATAWAY STATE: NJ ZIP: 08854 FORMER COMPANY: FORMER CONFORMED NAME: ENZON PHARMACEUTICALS INC DATE OF NAME CHANGE: 20021211 FORMER COMPANY: FORMER CONFORMED NAME: ENZON PHARMACEUTICAL INC DATE OF NAME CHANGE: 20021210 FORMER COMPANY: FORMER CONFORMED NAME: ENZON INC DATE OF NAME CHANGE: 19920703 8-K/A 1 c66554_8ka.htm

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K/A

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 10, 2011

ENZON PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation)

0-12957		22-2372868
(Commission File Number)		(IRS Employer Identification No.)

20 Kingsbridge Road

Piscataway, New Jersey 08854

(Address of Principal Executive Offices)

Registrant’s telephone number, including area code (732) 980-4500

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (16 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (16 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (16 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (16 CFR 240.13e-4(c)

Item 5.07 Submission of Matters to a Vote of Security Holders.

In connection with the results of the non-binding advisory vote on the frequency of future advisory votes on the compensation of the named executive officers of Enzon Pharmaceuticals, Inc. (the “Company”) at the Company’s Annual Meeting of Stockholders held on May 10, 2011 (the “Annual Meeting”), the Board of Directors decided that a non-binding advisory vote to approve the compensation of the named executive officers of the Company will be included annually in the Company’s proxy materials until the next vote on frequency, or until the Board of Directors otherwise determines that a different frequency for such advisory votes is in the best interests of the stockholders of the Company.

The results of the Annual Meeting were disclosed by the Company on a Current Report on Form 8-K filed on May 16, 2011 (the “Original Report”). This Current Report on Form 8-K/A amends the Original Report solely for the purpose of disclosing the Company’s decision on the frequency of future say-on-pay votes.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

ENZON PHARMACEUTICALS, INC.

By:	/s/ Andrew Rackear
	Name:	Andrew Rackear
	Title:	Vice President and General Counsel